Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease
Table 1
Characteristics of the patients on enrollment, per study group.
Edoxaban monotherapy (n = 74)
Combination therapy (n = 73)
value
Age, years
74 ± 7
74 ± 9
0.91
Male sex
64 (87)
63 (86)
0.97
BMI (m2/kg)
25 ± 4.9
24 ± 4.1
0.28
Weight (kg)
66 ± 15
65 ± 14
0.59
Height (cm)
162 ± 7.2
163 ± 7.4
0.62
Comorbidities
Current smoking
8 (11)
9 (12)
0.89
Hypertension
65 (88)
63 (86)
0.78
Diabetes mellitus
29 (39)
34 (47)
0.37
Hepatic function abnormal
3 (4)
1 (1)
0.62
Medical history
Previous PCI
64 (87)
60 (82)
0.47
Previous CABG
5 (7)
8 (11)
0.40
Myocardial infarction, peripheral artery disease, and aortic plaque
60 (81)
51 (70)
0.11
Previous stroke, transient ischemic attack, or systemic embolism
9 (12)
12 (16)
0.46
Valvular disease
3 (4.1)
4 (5.5)
0.88
Cancer
2 (2.7)
3 (4.1)
0.68
Past bleeding complications
10 (14)
8 (11)
0.90
Type of stent
Drug eluting
45 (61)
47 (64)
0.56
Bare metal
9 (12)
4 (6)
POBA
8 (11)
9 (12)
Only medication
12 (16)
13 (18)
DES system
SYNERGY
18 (45)
25 (53)
0.79
Orsiro
1 (2)
1 (2)
Ultimaster
7 (16)
2 (4)
Xience
5 (11)
6 (13)
Promus
6 (13)
5 (11)
Resolute integrity
2 (4)
3 (6)
Endeavor
1 (2)
0 (0)
TAXUS
1 (2)
1 (2)
Cypher
2 (4)
2 (4)
Unknown
2 (4)
2 (4)
Time from PCI to enrollment (d)
SYNERGY
313 (212, 473)
293 (243, 504)
0.99
Orsiro
201
324
Ultimaster
393 (206, 779)
1119
0.05
Xience
1966 (422, 2799)
979 (257, 2043)
0.43
Promus
1926 (1619, 2282)
2407 (1910, 3358)
0.15
Resolute integrity
1536
1505
0.75
Endeavor
2444
TAXUS
4379
2615
Cypher
4776
4750
0.92
1st or 2nd generation DES
1966 (1516, 3116)
1933 (1158, 2858)
0.67
3rd generation DES (SYNERGY, orsiro, ultimaster)
329 (206, 514)
310 (257, 514)
0.77
Bare metal stent
4666 (3836, 6492)
2927 (2304, 3273)
0.06
POBA
1485 (658, 4275)
974 (397, 2095)
0.63
Type of AF
Paroxysmal
13 (18)
14 (19)
0.91
Persistent
48 (65)
48 (65)
Permanent
13 (18)
11 (16)
Previous intervention other than PCI
Catheter ablation
7 (10)
9 (12)
0.69
Pacemaker implantation
3 (4)
3 (4)
Implantable cardioverter defibrillator
4 (5)
1 (1)
Cardiac resynchronization therapy
1 (1)
2 (3)
Prior antithrombotic drug therapy
Anticoagulants used
Warfarin
2 (3)
1 (1)
0.51
Dabigatran
5 (7)
1 (1)
0.11
Rivaroxaban
7 (10)
7 (10)
0.60
Apixaban
4 (6)
6 (8)
0.36
Edoxaban
54 (73)
55 (75)
0.74
Antiplatelets used
Aspirin
29 (39)
26 (36)
0.65
P2Y12
34 (46)
48 (66)
0.020
Cilostazol
3 (3)
1 (1)
1.0
None
13 (18)
5 (7)
0.08
Initial dose of edoxaban (mg)
60 mg
36 (49)
29 (40)
0.36
30 mg
38 (51)
43 (59)
15 mg
0
1 (1)
Use of proton pump inhibitors
59 (80)
64 (88)
0.19
CHADS2 score
2 (median)
2 (median)
0
0 (0)
0 (0)
0.25
1
14 (19)
9 (12)
2
33 (45)
27 (37)
3
16 (22)
23 (32)
4
5 (7)
11 (15)
5
5 (7)
3 (4)
6
1 (1)
0 (0)
CHA2DS2 -VASc score
4 (median)
4 (median)
0
0
0 (0)
0.26
1
1 (1)
0 (0)
2
4 (5)
7 (10)
3
13 (18)
13 (18)
4
31 (42)
21 (29)
5
14 (19)
16 (22)
6
5 (7)
13 (18)
7
5 (7)
3 (4)
8
1 (1)
0 (0)
HAS-BLED score
3 (median)
3 (median)
0
0 (0)
0 (0)
0.68
1
4 (5)
2 (3)
2
17 (23)
16 (22)
3
34 (46)
35 (48)
4
16 (22)
18 (25)
5
1 (1)
2 (3)
6
2 (3)
0 (0)
Laboratory test results
Hb
13.6 ± 1.7
13.4 ± 1.9
0.53
Creatinine clearance
58.3 ± 14
56.8 ± 16
0.52
NTproBNP
235 (151, 513)
411 (140, 661)
0.20
Data are shown as the number (%) of patients, mean ± SD values, or median (25th, 75th percentile) values. % = % of the total of 45 and 47 patients who underwent a DES implantation in the edoxaban monotherapy group and combination therapy group, respectively. AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass grafting; DES, drug eluting stent; Hb, hemoglobin; NT-pro BNP, N-terminal probrain natriuretic peptide; PCI, percutaneous coronary intervention; POBA, plain old balloon angioplasty. Determined by the t-test, chi-square test, or fisher’s exact test.
